Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Janssen-Cilag Pty Ltd
This trial includes a dose escalation and expansion component. Participants will receive an escalating or recommended dose of oral JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent or sponsor/investigator decision.